• Published 2014

Metronomic Cyclophosphamide andMethotrexate Chemotherapy Combined with 1 E 10 Anti-Idiotype Vaccine in Metastatic Breast Cancer

@inproceedings{Soriano2014MetronomicCA,
  title={Metronomic Cyclophosphamide andMethotrexate Chemotherapy Combined with 1 E 10 Anti-Idiotype Vaccine in Metastatic Breast Cancer},
  author={Jorge Luis Soriano and Noyde Batista and Eduardo Santiesteban and Mayt{\'e} Lima and Javier Gonz{\'a}lez and R. Garc{\'i}a and Yohanka Zarza and Ver{\'o}nica L{\'o}pez and Myriam Rodr{\'i}guez and Jorge L. Loys and NarcisoMontejo and Frank V. Aguirre and AmparoMacı́as and A. V{\'a}zquez},
  year={2014}
}
The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase the efficacy of the treatment. Twenty one patients with metastatic breast cancer in progression and a Karnosky index ≥60%, were treated with metronomic chemotherapy (50 mg of cyclophospamide orally… CONTINUE READING

Tables from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

The anti-angiogenic basis of metronomic chemotherapy

  • Nature Reviews Cancer
  • 2004
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Breast cancer (metastatic).

  • BMJ clinical evidence
  • 2010
VIEW 1 EXCERPT